EyeCyte
Partnering with esteemed institutions to pioneer new treatments for retinal diseases.
Partnering with esteemed institutions to pioneer new treatments for retinal diseases.
EyeCyte, Inc. is a biotechnology startup focused on pioneering new treatments for retinal diseases. Partnering with esteemed institutions such as Pfizer's Bioinnovation and io therapeutics Center, and The Scripps Research Institute, the company is dedicated to developing novel therapeutics for neovascular and degenerative retinal diseases. Established in 2005 and headquartered in the United States, the company received a significant $3.00M Series A investment on 23 June 2008, with the investment coming from Pfizer Venture Investments. EyeCyte's dedication to groundbreaking research and esteemed partnerships positions it as a promising player in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $3.00M | 1 | Pfizer Venture Investments | 23 Jun 2008 |
No recent news or press coverage available for EyeCyte.
We care about your data, and we'd love to use cookies make your experience better.